Implant Results Articles & Analysis
16 news found
William Welch, MD of the University of Pennsylvania and co-principal investigator of the LimiFlexIDE study added, "I am encouraged by the clinical outcomes and results we have seen so far in the study. LimiFlex is an exciting new possibility for patients currently undergoing fusion for degenerative spondylolisthesis and would offer much faster recovery for patients, significant ...
The trial has reached its target of 135 LimiFlex patients enrolled into the investigational arm of the trial; the control arm will continue enrolling subjects to its target of 160 patients. The results of the LimiFlex trial will form the basis for a PMA application to the U.S. ...
To date, a total of 168 study subjects have reached 12 months follow up. The results of the LimiFlex trial will form the basis for a PMA application to the U.S. ...
LimiFlex received the CE Mark in 2009 and has been implanted with excellent results in more than 2,000 European patients. Results to date, including this 10-year experience, show the potential for LimiFlex to provide a robust, motion-preserving, minimally invasive, outpatient solution. ...
LimiFlex received the CE Mark in 2009 and has been implanted with excellent results in more than 2,000 European patients. Results to date, including this 10-year experience, show the potential for LimiFlex to provide a robust, motion-preserving, minimally invasive, outpatient solution. ...
The accepted poster, “Interim Phase 2a Clinical Study Results with PA5108 Latanoprost Ocular Implant for the Treatment of Glaucoma” will be presented by Associate Professor Michael Coote, MD, a leading glaucoma specialist at Melbourne Eye Specialists and a principal investigator of the study. ...
LimiFlex received the CE mark in 2009 and has been implanted with excellent results in more than 2,000 European patients. Results to date, including 10-years' experience with the device in Europe, show the potential for LimiFlex to provide a robust, motion-preserving, minimally invasive, outpatient solution for this large patient population. ...
REDWOOD CITY, Calif., Jan. 19, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced receipt of FDA approval for expanded labeling for its Senza® Spinal Cord Stimulation (SCS) System for the treatment of Non-Surgical Refractory Back Pain (NSRBP). This approval ...
SENZA-PDN Randomized Controlled Trial Results Demonstrate Significant and Sustained Outcomes with 10 kHz Therapy at 18-Months Follow-Up. SENZA-NSRBP Randomized Controlled Trial Results Show Profound Improvements in Non-Surgical Refractory Back Pain Patients Receiving 10 kHz Therapy Relative to Conventional Medical Management at 12-Months Follow-Up. Both SENZA-PDN and SENZA-NSRBP Studies ...
Active Implants, LLC, a developer of orthopedic implant solutions for joint preservation, today announced two-year results of the MERCURY study, which showed that the company’s NUsurface® Meniscus Implant provides statistically superior pain relief beginning at six months compared to non-surgical therapy. ...
"As study data accumulates, we have more and more evidence that LimiFlex is on track to meet or exceed the clinical results we hoped for. The new funds will enable us to develop and submit a very strong PMA filing in the coming months." ...
The Alleviant System is a novel transcatheter device for the creation of a therapeutic interatrial shunt without a permanent cardiac implant. Results were presented at the American College of Cardiology Scientific Session (ACC.21) and at the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR 2021) by Colin Barker, MD, ...
It is made of an optically clear, foldable, biocompatible co-polymer with the mechanical strength to allow smooth and controlled insertion and easy intraocular manipulation – without the risk of damaging the implant (a potential issue with donor tissue). The end result: a strong, resilient graft that covers around 40 percent of the cornea’s area, ...
Initial post-implantation results from these patients, who received a 24mm valve, show favorable low aortic valve pressure gradients and no observed paravalvular leakage or aortic insufficiency. The Colibri TAVI System is being developed with 21mm, 24mm, 27mm and 30mm valves to accommodate a variety of clinical and patient needs. Thirty-day follow-up ...
Aix-en-Provence, November 16th, 2015 – GRAFTYS SA, a company which develops and commercializes biomaterials used in orthopedic surgery, announces that it has recently established an ambitious Post Marketing Surveillance program, in the form of an internationally based registry of patients who have received implants of GRAFTYS® HBS and GRAFTYS® QuickSet. Both of ...
ByGraftys
” TONY HICKSON, MANAGING DIRECTOR TECHNOLOGY TRANSFER AT IMPERIAL INNOVATIONS, SAID: “The science developed at Imperial is at the very forefront of orthopaedic implant technology and the result of thorough study and experimentation. ...